Stock Ratings / Health Care / CLYM / insiders

CRMD (62) IRWD (69) ACRS (31) NVCT (43) ⌘ Pro Terminal →

Climb Bio Inc. (CLYM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$10.33 +2.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Climb Bio Inc. (CLYM) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $593.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLYM)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CLYM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CLYM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CLYM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLYM)

✓Walkthrough of CLYM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLYM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.33%📐 HORIZONTAL RANGE

2026-10-30O $10.15H $10.51L $10.02C $10.33VOL 708.7K

RES: $22.00SUP: $8.51SMA50: $12.60SMA200: $10.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLYM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLYM Butterfly Map → + Track CLYM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLYM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLYM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLYM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLYM)

Health Care Rank #705 of 1016 ⚔️ CRMD vs CLYM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLYM vs. CRMD, IRWD, ACRS, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Climb Bio Inc. (CLYM) ranks #705 by composite RQD confidence (38/100, grade D-) and #423 by equity capitalization ($593.3M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CLYM at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLYM ACTIVE Climb Bio Inc.	D-	38/100	—	—	-35.0%	+2.08%	$593.3M	Benchmark Subject
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-6.83%	$595.5M	/crmd-vs-clym →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C+	69/100	24.9x	—	85.0%	+0.28%	$598.2M	/irwd-vs-clym →
ACRS Aclaris Therapeutics Inc.	E	31/100	—	73.3%	-35.0%	+0.76%	$587.3M	/acrs-vs-clym →
NVCT Nuvectis Pharma Inc.	D-	43/100	—	—	-35.0%	+1.14%	$605.6M	/nvct-vs-clym →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001768446

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Climb Bio Inc. (CLYM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$59.9M, operating cash flow of -$54.4M, and free cash flow of -$54.5M (-250.5% YoY). On the balance sheet, CLYM closed FY2025 with $167.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$59.9M	-$54.4M	-$54.5M	$167.7M	—
FY2024 (FY)	2024-12-31	$0	-$73.9M	-$15.6M	-$15.6M	$217.2M	—
FY2023 (FY)	2023-12-31	$0	-$35.1M	-$20.6M	-$20.6M	—	—

3. CLYM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLYM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Climb Bio Inc. (NASDAQ: CLYM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $10.33 (+2.08% 1D, market cap $593.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLYM ranks #705 in composite RQD confidence.

How does CLYM compare to CRMD and IRWD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLYM carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRMD (CorMedix Inc.) holds a C grade (62/100 RQD, P/E 3.7x, ROIC 45.5%, cap $595.5M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C+ grade (69/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLYM?

Per CLYM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768446), Climb Bio Inc. generated $0 in revenue, -$59.9M in net income, and -$54.5M in free cash flow against $167.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLYM trading relative to its 50-day, 200-day, and 52-week technical levels?

CLYM last traded at $10.33 (+2.08% on volume of 688,999 shares), positioning the stock -18.02% below its 50-day simple moving average ($12.60) and -0.48% below its 200-day simple moving average ($10.38). Across its 52-week range of $1.64 to $18.33, CLYM sits at the 52.1% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.04 to $11.62).

CLYM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CLYM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CLYM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CLYM RQD Cockpit CLYM 12M Forecast CLYM Earnings & Move CLYM Dividends & DRIP CLYM Insiders & 13F CLYM Whale Options CLYM Profit Sankey CLYM News & Why